AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has highlighted progress across its clinical pipeline and reaffirmed its financial outlook during its 2026 Virtual Investor Day, outlining plans to advance its lead candidate BPL-003 into Phase 3 trials for treatment-resistant depression while continuing development of additional mental health therapies. The clinical-stage biotechnology company said it remains on track to initiate two parallel Phase 3 pivotal studies of BPL-003, a mebufotenin benzoate nasal spray, in the second quarter of 2026 following a successful End-of-Phase 2 meeting with the US Food and Drug Administration.